{"id":"aeras-404","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"}]},"_chembl":{"chemblId":"CHEMBL3652530","moleculeType":"Small molecule","molecularWeight":"407.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AERAS-404 is a novel vaccine candidate that aims to provide long-term protection against tuberculosis by stimulating the immune system to recognize and respond to the bacteria that cause the disease. The vaccine has been engineered to express a specific protein from the Mycobacterium tuberculosis bacteria, which triggers an immune response that can help prevent infection.","oneSentence":"AERAS-404 is a vaccine designed to protect against tuberculosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:21:12.566Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis"}]},"trialDetails":[{"nctId":"NCT02075203","phase":"PHASE2","title":"Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents","status":"COMPLETED","sponsor":"Aeras","startDate":"2014-02","conditions":"Tuberculosis","enrollment":989},{"nctId":"NCT01861730","phase":"PHASE1, PHASE2","title":"Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants","status":"COMPLETED","sponsor":"Aeras","startDate":"2013-07-01","conditions":"Tuberculosis","enrollment":243},{"nctId":"NCT02420444","phase":"PHASE1","title":"A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults","status":"COMPLETED","sponsor":"Aeras","startDate":"2011-01","conditions":"Tuberculosis","enrollment":70},{"nctId":"NCT02109874","phase":"PHASE1","title":"A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)","status":"COMPLETED","sponsor":"Aeras","startDate":"2008-12","conditions":"Tuberculosis","enrollment":40},{"nctId":"NCT02074956","phase":"PHASE1","title":"A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults","status":"COMPLETED","sponsor":"Aeras","startDate":"2008-05","conditions":"Tuberculosis","enrollment":60},{"nctId":"NCT02066428","phase":"PHASE1","title":"A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection","status":"COMPLETED","sponsor":"Aeras","startDate":"2007-11","conditions":"Tuberculosis","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["H4","H4:IC31"],"phase":"phase_2","status":"active","brandName":"AERAS-404","genericName":"AERAS-404","companyName":"Aeras","companyId":"aeras","modality":"Biologic","firstApprovalDate":"","aiSummary":"AERAS-404 is a vaccine designed to protect against tuberculosis. Used for Tuberculosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}